Video

Our team behind the scenes at SXSW | Next steps: From molecule design to medicine

Following target identification and endotyping, we have the ability to design molecule compounds and progress these into clinical trials. In this final video, our team walks through our approach in this video to conclude the series from our SXSW keynote session.

Our team was able to identify lists of possible gene targets involved in disease by applying AI models on diverse sets of data such as scientific literature, patents, chemical databases, and patient data such as electronic health records or multi-omics datasets.

Following the generation of the list of targets, molecular design can start. Here we try to tackle an important aspect of making the drug brain penetrant. This is an important step where our team of scientists and machine learning researchers identify, design and test the best molecules.

The collaboration between our scientists and machine learning researchers gives us the ability to rethink and improve the process of drug discovery and development. Patients are at the heart of everything we do and this is reflected in our approach.

More Posts

You Might Also Like

Blog
Tech Nation Visa: the gateway to world-leading UK tech jobs
Drawing attention to the Tech Nation Visa, a great initiative that enables the brightest international talent to live and work in the UK.
Feb 19, 2021
News
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.
Feb 11, 2021
News
BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target
BenevolentAI and AstraZeneca hit collaboration milestone with an AI-generated CKD target from the partnership entering AstraZeneca’s portfolio.
Jan 27, 2021
News
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed data from the ACTT-2 further validate BenevolentAI’s hypothesis for baricitinib as a potential COVID-19 treatment.
Jan 15, 2021
Blog
Joanna Shields speaks at the Global Partnership on Artificial Intelligence
BenevolentAI CEO Joanna Shields opened the final plenary of the Global Partnership on Artificial Intelligence (GPAI) summit with a powerful message on the future of AI.
Dec 11, 2020
Blog
BenevolentAI wins Innovation Award at 2020 Scrip Awards
BenevolentAI wins the Innovation Award at the prestigious 2020 Scrip Awards for our work in artificial intelligence applied drug discovery.
Dec 11, 2020